AbbVie (NYSE:ABBV) said on Wednesday that its late-stage study testing atogepant in comparison with the highest dose of ...

AbbVie’s latest Phase 3 TEMPLE study delivers a real headache for migraines—and topiramate. The study found that patients ...

AbbVie's study also met all secondary goals, with 64.1% patients on Qulipta seeing a 50% or more reduction in the average ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...

Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He has long wanted to ...

In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.

Health and Human Services Secretary Robert F. Kennedy Jr. wants to make it harder and more expensive for drug companies to advertise to patients.

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...

This was the stock's third consecutive day of losses.

Some say that Dividend Investing is boring, claiming that dividend stocks are low growth and offer near-flat capital appreciation compared to the latest investment trends. But when all things fail, ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...